Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable



    
           - President of Bioniche Food Safety an invited speaker -
    

    BELLEVILLE, ON, Feb. 3 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC), a
research-based, technology-driven Canadian biopharmaceutical company,
announced that its President of Bioniche Food Safety, Rick Culbert, is today
participating in a Canadian Beef Value Chain Roundtable in Gatineau, Quebec.
The two-day Roundtable involves representatives from regulatory authorities,
ranchers, feedlot operators, processors, retail and food service
representatives, feed suppliers and others. They are meeting to develop a
strategy focused on improving competitiveness of the Canadian beef industry
through market access and development, the regulatory environment, research
and innovation and information transfer.
    In his presentation to the Roundtable, Mr. Culbert will be sharing
information about the Company's Econiche(TM) cattle vaccine, the world's first
vaccine developed to reduce the shedding by cattle of Escherichia coli (E.
coli) O157. Econiche is fully licensed for sale in Canada by the Canadian Food
Inspection Agency (CFIA).
    The vaccine has the potential to significantly reduce the amount of E.
coli O157 shed into the environment by beef and dairy cattle and, in turn,
reduce the risk to human health. An outbreak of human infection with E. coli
O157 last fall in North Bay, Ontario, Canada involved 250 people reporting
symptoms 50 lab-confirmed cases of human illness including one case of
Haemolytic Uremic Syndrome (HUS). The illnesses were associated with a
Harvey's Restaurant in that community.
    Most strains of E. coli are harmless but some, like O157:H7, can cause
severe illness and even be fatal when ingested by humans from contaminated
meat, vegetables or water. Vaccination of cattle with Econiche can help reduce
the risk of food and waterborne contamination with E. coli O157. Cows carry E.
coli O157:H7 but they don't get sick. Where the disease comes from is people
encountering contaminated food or water, usually from cow feces.
    On-farm interventions to reduce the shedding of E. coli O157 by cattle,
such as simple vaccination of cattle with Econiche, have the potential to
reduce food and water contamination and the consequences associated with human
infection with the deadly bacteria. Clinical trials conducted with Econiche
have shown a significant reduction in the amount of E. coli shed in the manure
of vaccinated cows.
    "At today's Beef Value Chain Roundtable, I will be discussing the
collaborative Canadian partnership that led to the development of Econiche,"
said Rick Culbert, President of Bioniche Food Safety. "I will also share
information about the opportunity that vaccination of Canadian cattle
represents beyond protecting public health, that is, a potential enhancement
of the competitiveness of Canadian beef in export markets, where the vaccine
is not yet available to producers."

    About the Beef Value Chain Roundtable

    The Beef Value Chain Roundtable was launched in January, 2003 and emerged
as a key vehicle for helping ensure a coordinated response to Bovine
Spongiform Encephalopathy (BSE) and as a key focal point for various working
groups to engage with representatives of the entire beef value chain. Now more
focused on long-term issues, membership on the beef roundtable includes
ranchers, feedlot operators, processors, retail and food service
representatives, feed suppliers and others.

    About Bioniche Life Sciences Inc.

    Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery, development,
manufacturing, and marketing of proprietary products for human and animal
health markets worldwide. The fully-integrated company employs approximately
200 skilled personnel and has three operating divisions: Human Health, Animal
Health, and Food Safety. The Company's primary goal is to develop proprietary
cancer therapies supported by revenues from marketed products in human and
animal health. Bioniche has been named one of the Top 50 Best Small and
Medium-Sized Employers in Canada for 2009. For more information, please visit
www.Bioniche.com.

    Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current expectation
regarding future events. These forward-looking statements involve risk and
uncertainties, which may cause, but are not limited to, changing market
conditions, the successful and timely completion of clinical studies, the
establishment of corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the regulatory
approval process, and other risks detailed from time to time in the Company's
ongoing quarterly and annual reporting.

    %SEDAR: 00013159EF




For further information:

For further information: Jennifer Shea, Vice-President, Communications,
Investor & Government Relations, Bioniche Life Sciences Inc., Telephone: (613)
966-8058, Cell: (613) 391-2097, Jennifer.Shea@Bioniche.com

Organization Profile

Telesta Therapeutics Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890